$60.29 +0.77 (%) AbbVie Inc - NYSE

Oct. 24, 2014 | 04:00 PM

Partner Headlines

  1. Shire: Who Needs AbbVie?

    IBD | Oct. 24, 2014 | 18:46PM EST
  2. Shire EPS Growth Accelerates, Stock Continues Rebound

    IBD | Oct. 24, 2014 | 11:12AM EST
  3. Gilead's Hep C Dream Drug Faces Demanding Investors

    IBD | Oct. 22, 2014 | 16:44PM EST
  4. Making Money With Charles Payne: 10/20/14

    FoxBusiness | Oct. 21, 2014 | 18:00PM EST
  5. Celgene Reports More Good Crohn's Disease Data

    IBD | Oct. 21, 2014 | 11:32AM EST
  6. #PreMarket Primer: Tuesday, October 21: China's Third Quarter Growth Disappoints

    Benzinga | Oct. 21, 2014 | 07:45AM EST
  7. Must Watch Stocks For October 21, 2014

    Benzinga | Oct. 21, 2014 | 04:04AM EST
  8. AbbVie Unveils $5 Billion Buyback; Blames U.S. For Failed Inversion

    Benzinga | Oct. 20, 2014 | 20:20PM EST
  9. Benzinga's M&A Chatter for Monday October 20, 2014

    Benzinga | Oct. 20, 2014 | 19:27PM EST
  10. ABBVIE

    IBD | Oct. 20, 2014 | 18:57PM EST
  11. Announcement Of Termination Of Proposed AbbVie And Shire Transaction

    Benzinga | Oct. 20, 2014 | 17:13PM EST
  12. Enanta Pharma Reports Update on Collaboration Deal with AbbVie: Will Not Exercise Option for Co-Development, Co. Received $57M Related to Signing, $95M in Milestones

    Benzinga | Oct. 20, 2014 | 16:56PM EST
  13. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD | Oct. 20, 2014 | 11:16AM EST
  14. Benzinga's Weekend M&A Chatter

    Benzinga | Oct. 19, 2014 | 21:58PM EST
  15. UPDATE: Bank Of America Reiterates On AbbVie On Move To Standalone Valuation

    Benzinga | Oct. 17, 2014 | 09:44AM EST
  16. Benzinga's M&A Chatter for Thursday October 16, 2014

    Benzinga | Oct. 17, 2014 | 00:02AM EST
  17. Shire may have to go it alone

    IBD | Oct. 16, 2014 | 18:59PM EST
  18. Shire Can Thrive Without AbbVie, Say Analysts

    IBD | Oct. 16, 2014 | 11:19AM EST
  19. Benzinga's Volume Movers

    Benzinga | Oct. 16, 2014 | 10:36AM EST
  20. Wall Street Drops on Continued Global Concerns

    FoxBusiness | Oct. 16, 2014 | 10:10AM EST
  21. AbbVie Board To Shareholders: Vote No On Shire Buy

    IBD | Oct. 16, 2014 | 00:52AM EST
  22. CNBC's Stock Pops & Drops From October 15: Twitter, Gogo And GoPro

    Benzinga | Oct. 15, 2014 | 20:30PM EST
  23. Benzinga's M&A Chatter for Wednesday October 15, 2014

    Benzinga | Oct. 15, 2014 | 20:01PM EST
  24. AbbVie Rethinking Shire Deal

    IBD | Oct. 15, 2014 | 18:40PM EST
  25. Was Celgene's Crohn's Disease Drug Worth The Price?

    IBD | Oct. 15, 2014 | 17:39PM EST
  26. Markets Rebound After Getting Crushed Intraday, Still Close Lower

    Benzinga | Oct. 15, 2014 | 16:57PM EST
  27. KeyCorp Falls On Downbeat Results; Penford Shares Climb

    Benzinga | Oct. 15, 2014 | 15:15PM EST
  28. Google Spending Impact On Q3 Profit Margins Eyed

    IBD | Oct. 15, 2014 | 14:33PM EST
  29. Dow Tumbles More Than 300 Points; CSR Plc Shares Surge On Acquisition News

    Benzinga | Oct. 15, 2014 | 13:49PM EST
  30. Shire Falls, AbbVie Questioned On Buyout Backtrack

    IBD | Oct. 15, 2014 | 13:11PM EST
  31. Markets Drop; Bank Of America Posts Upbeat Earnings

    Benzinga | Oct. 15, 2014 | 11:15AM EST
  32. Stocks Dive, Then Pare Losses; Shire, Expedia, KeyCorp Crumble

    IBD | Oct. 15, 2014 | 10:37AM EST
  33. Bank Of America: AbbVie's Decision To Reconsider Merger With Shire 'A Surprise To Us'

    Benzinga | Oct. 15, 2014 | 10:32AM EST
  34. Morning Market Losers

    Benzinga | Oct. 15, 2014 | 09:57AM EST
  35. Stock Futures Swoon After Data; Shire Plunges As AbbVie Balks

    IBD | Oct. 15, 2014 | 09:02AM EST
  36. Shire Shares Plummet On Possible Buyout Cancellation

    Benzinga | Oct. 15, 2014 | 08:55AM EST
  37. Benzinga's Top #PreMarket Losers

    Benzinga | Oct. 15, 2014 | 08:13AM EST
  38. Fast Money Halftime Report Final Trade From October 14

    Benzinga | Oct. 14, 2014 | 16:50PM EST
  39. AbbVie Reports Late-Breaking Results from Phase 3 Trial of HUMIRA, Has Met Primary Endpoint in PIONEER II

    Benzinga | Oct. 13, 2014 | 09:21AM EST
  40. Gilead's Hep C Combo Pill Harvoni Approved, Priced

    IBD | Oct. 10, 2014 | 15:13PM EST
  41. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD | Oct. 8, 2014 | 13:36PM EST
  42. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD | Oct. 7, 2014 | 19:33PM EST
  43. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD | Oct. 7, 2014 | 11:13AM EST
  44. Jazz Pharmaceuticals Uses New Cash To Buy For Growth

    IBD | Oct. 3, 2014 | 14:39PM EST
  45. Markets Little Changed Ahead Of Friday's Jobs Report

    Benzinga | Oct. 2, 2014 | 17:10PM EST
  46. Pharma Stocks: Surprising Shift In U.S. Drug Market

    YCharts | Sep. 29, 2014 | 08:15AM EST
  47. There's More to Gilead Sciences than a Successful Drug

    GuruFocus | Sep. 26, 2014 | 19:07PM EST
  48. AbbVie Inc Spikes On Reported End-Run Around Inversion Rules

    Benzinga | Sep. 26, 2014 | 11:21AM EST
  49. A Few Reasons Why AbbVie's Momentum Will Continue

    GuruFocus | Sep. 25, 2014 | 17:53PM EST
  50. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD | Sep. 24, 2014 | 17:29PM EST
Trading Center